BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)
Published: Sept. 30, 2024
Language: Английский
European Journal of Immunology, Journal Year: 2024, Volume and Issue: 54(5)
Published: April 3, 2024
Summary Live‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers particularly broad and polyfunctional response engaging multiple arms of innate, humoral cellular immunity. This unique immunogenicity translates into an extraordinary efficacy outstanding longevity protection, possibly by single‐dose immunization. More recently, progress molecular virology synthetic biology allowed engineering powerful vector promising platform development novel recombinant live vaccines, including two licensed against Japanese encephalitis dengue, even paediatric use. Likewise, numerous chimeric transgenic preclinical candidates have been described. These include prophylactic emerging viral infections (e.g. Lassa, Zika SARS‐CoV‐2) parasitic diseases malaria), well therapeutic applications targeting persistent HIV chronic hepatitis), cancer. Efforts to overcome historical safety concerns manufacturing challenges are ongoing pave way wider use YF17D‐based vaccines. In this review, we summarize recent insights regarding platform, how may complement differentiate from other modalities unmet medical needs pandemic preparedness.
Language: Английский
Citations
7
Trends in Microbiology, Journal Year: 2024, Volume and Issue: 32(8), P. 756 - 768
Published: Feb. 15, 2024
Language: Английский
Citations
6
Molecular Biotechnology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 9, 2025
Language: Английский
Citations
0
Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(1)
Published: Jan. 1, 2025
ABSTRACT As the COVID‐19 pandemic continues, increasingly complex vaccination and infection histories have made it urgent to investigate antibody dynamics in populations with hybrid immunity. This study aimed explore multi‐time‐point of SARS‐CoV‐2 IgG levels a community‐based population Jiangsu Province, China, following Omicron BA.5 wave, as well long‐term persistence antibodies nearly 2 years postinfection. A total 2737 participants across Province were followed up at three different time points over 6‐month period (December 2022–June 2023). Additionally, cross‐sectional serological survey was conducted October 2024, involving 230 assess persistence. We used generalized additive models fit curves, linear mixed factors influencing levels, Kaplan‐Meier survival analysis estimate cumulative seroreversion rates. Our findings revealed that, large‐scale infections, 85% initially exhibited seropositive levels. Older individuals (> 65 years) had significantly lower faster rates decline compared younger participants. Booster immunization reduced risk by 59.79% (95% CI: 29.63%–76.46%), while multiple infections experienced slower decay. In 22 months postinfection, seropositivity rate remained high, exceeding 98%, indicating sustained immunity level. provides valuable insights into infection. The results underscore importance tailored booster strategies sustain immunity, especially vulnerable groups like elderly. ongoing monitoring is essential for assessing informing future strategies.
Language: Английский
Citations
0
Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(1)
Published: Jan. 1, 2025
ABSTRACT A total of 5011 adult volunteers attending vaccination centers in different regions Colombia were enrolled a 1‐year prospective observational cohort study to evaluate the immunogenicity and effectiveness SARS‐CoV‐2‐based vaccines as part National Vaccine Program established contain COVID‐19 pandemic. Following informed consent, 5,011 participants underwent sociodemographic survey PCR testing assess SARS‐CoV‐2 infection. Blood samples collected, serum fractions obtained from participant subsample ( n = 3441) at six‐time points virus‐specific IgG responses Spike protein, its Receptor Binding Domain, Nucleoprotein by ELISA. Additionally, antibody‐neutralizing activity was evaluated using cPass neutralization kit. Most (95.8%; 4802) received between one Ad26. COV2.S (Janssen vaccine) four vaccine doses BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA‐1273 (Moderna), CoronaVac (Sinovac), with some receiving combinations; small group, 4.2% 209), remained unvaccinated. Throughout study, only 8.76% 439) tested positive for PCR. Notably, all seroconverted antibodies, high seropositivity rates S (99.8%; 4795), RBD (99.7%; 1691), N (92.7%; 3072) proteins. Moreover, significant (92%–97%) neutralizing observed circulating variants. This highlights importance assessing duration response elicited infection, antibody potential surrogate marker protection. These findings provide important insight further strengthening strategies control COVID‐19.
Language: Английский
Citations
0
Influenza and Other Respiratory Viruses, Journal Year: 2025, Volume and Issue: 19(1)
Published: Jan. 1, 2025
ABSTRACT SARS‐CoV‐2, which originated in China late 2019, quickly fueled the global COVID‐19 pandemic, profoundly impacting health and economy worldwide. A series of vaccines, mostly based on full SARS‐CoV‐2 Spike protein, were rapidly developed, showing excellent humoral cellular responses high efficacy against both symptomatic infection severe disease. However, viral evolution waning neutralizing strongly challenged vaccine long term effectiveness, mainly infection, making necessary a strategy repeated updated booster shots. In this vaccination context, antibody repertoire diversification was evidenced, although immune imprinting after doses or reinfection also demonstrated identified as major determinant immunological to antigen exposures. Considering that small domain receptor binding (RBD), is target antibodies concentrates most mutations, following text aims provide insights into ongoing debate over best strategies for boosters. We address relevance developing new vaccines evolving RBD, thus focusing relevant antigenic sites variants. combination with immunofusing computerized approaches could minimize imprinting, therefore optimizing efficacy.
Language: Английский
Citations
0
Scientific Data, Journal Year: 2025, Volume and Issue: 12(1)
Published: Jan. 30, 2025
Language: Английский
Citations
0
Science Advances, Journal Year: 2025, Volume and Issue: 11(7)
Published: Feb. 12, 2025
Immune suppression poses a challenge to vaccine immunogenicity. We show that serum antibody neutralization against SARS-CoV-2 Omicron descendants was largely absent post-doses 1 and 2 in individuals with vasculitis treated rituximab. Detectable increasing neutralizing titers were observed 3 4, except for XBB. Rituximab exacerbates deficits over standard immunosuppressive therapy, although impairment resolves time since dosing. discordance between detectable IgG binding activity specifically the context of rituximab use, high proportions showing reasonable titer but no neutralization. ADCC response more frequently compared rituximab, indicating notable proportion antibodies are non-neutralizing. Therefore, use is associated severe despite repeated vaccinations, better preservation non-neutralizing activity.
Language: Английский
Citations
0
Biomolecules, Journal Year: 2025, Volume and Issue: 15(2), P. 280 - 280
Published: Feb. 14, 2025
Spike protein is a surface glycoprotein of the SARS-CoV-2 coronavirus, providing interaction coronavirus with angiotensin-converting enzyme 2 (ACE2) on host cell. The cytoplasmic tail S plays an important role in intracellular transport and translocation to plasma membrane. domain contains binding sites for COPI, COPII, SNX27, which are required trafficking this glycoprotein. In addition, S-palmitoylation sites. increases hydrophobicity by regulating its has signaling sequence that provides ERM family proteins, may mediate communication between cell membrane actin cytoskeleton. This review examines Understanding these processes necessary not only development vaccines based mRNA or adenovirus vectors encoding full-length spike (S) protein, but also therapy new infection (COVID-19).
Language: Английский
Citations
0
Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 185, P. 117936 - 117936
Published: March 8, 2025
Language: Английский
Citations
0